{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:18:06Z","timestamp":1773260286318,"version":"3.50.1"},"reference-count":82,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"abstract":"<jats:p>In 2003, an international committee of physicians and researchers in the field of acne, working together as the Global Alliance to Improve Outcomes in Acne, developed consensus guidelines for the treatment of acne. These guidelines were evidence based when possible but also included the extensive clinical experience of this group of international dermatologists. As a result of the evaluation of available data and the experience, significant changes occurred in the management routines for acne. The greatest change arose on the basis of improved understanding of acne pathophysiology. The recommendation now is that acne treatments should be combined to target as many pathogenic factors as possible. A topical retinoid should be the foundation of treatment for most patients with acne, because retinoids target the microcomedo, the precursor to all acne lesions. Retinoids also are comedolytic and have intrinsic antiinflammatory effects, thus targeting 2 pathogenic factors in acne.Combining a topical retinoid with an antimicrobial agent targets 3 pathogenic factors, and clinical trials have shown that comination therapy results in significantly faster and greater clearing as opposed to antimicrobial therapy alone.Oral antibiotics should be used only in moderate-to-severe acne, should not be used as monotherapy, and should be discontinued as soon as possible (usually within 8\u201312 weeks).Because of their effect on the microcomedo, topical retinoids also are recommended as an important facet of maintenance therapy.<\/jats:p>","DOI":"10.1542\/peds.2005-2022","type":"journal-article","created":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T21:17:38Z","timestamp":1157145458000},"page":"1188-1199","source":"Crossref","is-referenced-by-count":92,"title":["Expert Committee Recommendations for Acne Management"],"prefix":"10.1542","volume":"118","author":[{"given":"Andrea L.","family":"Zaenglein","sequence":"first","affiliation":[{"name":"Department of Dermatology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane M.","family":"Thiboutot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2006,9,1]]},"reference":[{"key":"2021120822585007400_R1","doi-asserted-by":"crossref","unstructured":"Leyden JJ. New understandings of the pathogenesis of acne. J Am Acad Dermatol.\u20081995;32:S15\u2013S25","DOI":"10.1016\/0190-9622(95)90416-6"},{"key":"2021120822585007400_R2","doi-asserted-by":"crossref","unstructured":"Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J.\u20081979;1(6171):1109\u20131110","DOI":"10.1136\/bmj.1.6171.1109"},{"key":"2021120822585007400_R3","doi-asserted-by":"crossref","unstructured":"Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol.\u20082003;49(1 suppl):S1\u2013S37","DOI":"10.1067\/mjd.2003.618"},{"key":"2021120822585007400_R4","doi-asserted-by":"crossref","unstructured":"Pochi PE, Strauss JS, Downing DT. Age-related changes in sebaceous gland activity. J Invest Dermatol.\u20081979;73:108\u2013111","DOI":"10.1111\/1523-1747.ep12532792"},{"key":"2021120822585007400_R5","doi-asserted-by":"crossref","unstructured":"Pochi PE, Strauss JS. Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol.\u20081974;62:191\u2013201","DOI":"10.1111\/1523-1747.ep12676783"},{"key":"2021120822585007400_R6","doi-asserted-by":"crossref","unstructured":"Gollnick HPM, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A. Pathogenesis and pathogenesis related treatment of acne. J Dermatol.\u20081991;18:489\u2013499","DOI":"10.1111\/j.1346-8138.1991.tb03122.x"},{"key":"2021120822585007400_R7","doi-asserted-by":"crossref","unstructured":"Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. Activity of the type 1 5-\u03b1-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol.\u20081995;105:209\u2013214","DOI":"10.1111\/1523-1747.ep12317162"},{"key":"2021120822585007400_R8","doi-asserted-by":"crossref","unstructured":"Thiboutot D, Knaggs H, Gilliland H, Lin G. Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology.\u20081998;196:38\u201342","DOI":"10.1159\/000017863"},{"key":"2021120822585007400_R9","doi-asserted-by":"crossref","unstructured":"Thiboutot DM, Knaggs H, Gilliland K, Hagari S. Activity of type 1 5\u03b1-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol.\u20081997;136:166\u2013171","DOI":"10.1111\/j.1365-2133.1997.tb14889.x"},{"key":"2021120822585007400_R10","doi-asserted-by":"crossref","unstructured":"Chen W, Zouboulis CC, Fritsch M, Kodelja V, Orfanos CE. Heterogeneity and quantitative differences of type 1 5\u03b1-reductase expression in cultured skin epithelial cells. Dermatology.\u20081998;196:51\u201352","DOI":"10.1159\/000017866"},{"key":"2021120822585007400_R11","doi-asserted-by":"crossref","unstructured":"Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol.\u20082001;116:793\u2013800","DOI":"10.1046\/j.1523-1747.2001.01312.x"},{"key":"2021120822585007400_R12","doi-asserted-by":"crossref","unstructured":"Schmidt JB, Spona J, Huber J. Androgen receptor in hirsutism and acne. Gynecol Obstet Invest.\u20081986;22:206\u2013211","DOI":"10.1159\/000298915"},{"key":"2021120822585007400_R13","doi-asserted-by":"crossref","unstructured":"Holmes RL, Williams M, Cunliffe WJ. Pilo-sebaceous duct obstruction and acne. Br J Dermatol.\u20081972;87:327\u2013332","DOI":"10.1111\/j.1365-2133.1972.tb07418.x"},{"key":"2021120822585007400_R14","doi-asserted-by":"crossref","unstructured":"Plewig G, Fulton JE, Kligman AM. Cellular dynamics of comedo formation in acne vulgaris. Arch Dermatol Forsch.\u20081971;242:12\u201329","DOI":"10.1007\/BF00595286"},{"key":"2021120822585007400_R15","unstructured":"Kurokawa I, Mayer-da-Silva A, Gollnick H, Orfanos CE. Occurrence and distribution of cytokeratins and filaggrin in the human pilosebaceous unit: an immunocytochemical study. In: Marks R, Plewig G, eds. Acne and Related Disorders. London, England: Martin Dunitz; 1989:19\u201322"},{"key":"2021120822585007400_R16","doi-asserted-by":"crossref","unstructured":"Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol.\u20082000;142:1084\u20131091","DOI":"10.1046\/j.1365-2133.2000.03531.x"},{"key":"2021120822585007400_R17","doi-asserted-by":"crossref","unstructured":"Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol.\u20081975;65:382\u2013384","DOI":"10.1111\/1523-1747.ep12607634"},{"key":"2021120822585007400_R18","doi-asserted-by":"crossref","unstructured":"Norris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol.\u20081988;118:651\u2013659","DOI":"10.1111\/j.1365-2133.1988.tb02566.x"},{"key":"2021120822585007400_R19","doi-asserted-by":"crossref","unstructured":"Toyoda M, Morohashi M. Pathogenesis of acne. Med Electron Microsc.\u20082001;34:29\u201340","DOI":"10.1007\/s007950100002"},{"key":"2021120822585007400_R20","doi-asserted-by":"crossref","unstructured":"Puhvel SM, Sakamoto M. The chemoattractant properties of comedonal components. J Invest Dermatol.\u20081978;71:324\u2013329","DOI":"10.1111\/1523-1747.ep12529815"},{"key":"2021120822585007400_R21","doi-asserted-by":"crossref","unstructured":"Cunliffe WJ. The sebaceous gland and acne: 40 years on. Dermatology.\u20081998;196:9\u201315","DOI":"10.1159\/000017859"},{"key":"2021120822585007400_R22","doi-asserted-by":"crossref","unstructured":"Leyden JJ. Therapy for acne vulgaris. N Engl J Med.\u20081997;336:1156\u20131162","DOI":"10.1056\/NEJM199704173361607"},{"key":"2021120822585007400_R23","doi-asserted-by":"crossref","unstructured":"Draelos ZK. Patient compliance: enhancing clinician abilities and strategies. J Am Acad Dermatol.\u20081995;32:S42\u2013S48","DOI":"10.1016\/0190-9622(95)90419-0"},{"key":"2021120822585007400_R24","doi-asserted-by":"crossref","unstructured":"Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology.\u20081998;196:119\u2013125","DOI":"10.1159\/000017844"},{"key":"2021120822585007400_R25","doi-asserted-by":"crossref","unstructured":"Thielitz A, Helmdach M, Ro\u0308pke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol.\u20082001;145:19\u201327","DOI":"10.1046\/j.1365-2133.2001.04276.x"},{"key":"2021120822585007400_R26","doi-asserted-by":"crossref","unstructured":"Verschoore M, Bouclier M, Czernielewski J, Hensby C. Topical retinoids: their uses in dermatology. Dermatol Clin.\u20081993;11:107\u2013115","DOI":"10.1016\/S0733-8635(18)30287-0"},{"key":"2021120822585007400_R27","doi-asserted-by":"crossref","unstructured":"Hensby C, Cavey D, Bouclier M, et al. The in vivo and in vitro anti-inflammatory activity of CD271: a new retinoid-like modulator of cell differentiation. Agents Actions.\u20081990;29:56\u201358","DOI":"10.1007\/BF01964720"},{"key":"2021120822585007400_R28","doi-asserted-by":"crossref","unstructured":"Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol.\u20081969;99:469\u2013476","DOI":"10.1001\/archderm.99.4.469"},{"key":"2021120822585007400_R29","doi-asserted-by":"crossref","unstructured":"Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol.\u20081996;34:482\u2013485","DOI":"10.1016\/S0190-9622(96)90443-0"},{"key":"2021120822585007400_R30","doi-asserted-by":"crossref","unstructured":"Gollnick H, Schramm M. Topical therapy in acne. J Eur Acad Dermatol Venereol.\u20081998;11(suppl 1):S8\u2013S12; discussion S28\u2013S29","DOI":"10.1111\/j.1468-3083.1998.tb00901.x"},{"key":"2021120822585007400_R31","doi-asserted-by":"crossref","unstructured":"Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol.\u20081978;58:555\u2013557","DOI":"10.2340\/0001555558555557"},{"key":"2021120822585007400_R32","doi-asserted-by":"crossref","unstructured":"Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double-blind, vehicle-controlled multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol.\u20081998;38:S24\u2013S30","DOI":"10.1016\/S0190-9622(98)70142-2"},{"key":"2021120822585007400_R33","doi-asserted-by":"crossref","unstructured":"Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter, double-blind, parallel study. J Am Acad Dermatol.\u20081998;38:S17\u2013S23","DOI":"10.1016\/S0190-9622(98)70141-0"},{"key":"2021120822585007400_R34","doi-asserted-by":"crossref","unstructured":"Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol.\u20081998;139(suppl 52):8\u201311","DOI":"10.1046\/j.1365-2133.1998.1390s2008.x"},{"key":"2021120822585007400_R35","unstructured":"Retin-A [package insert: full prescribing information]. Skillman, NJ: Ortho Dermatological; 2002"},{"key":"2021120822585007400_R36","doi-asserted-by":"crossref","unstructured":"Dunlap FE, Mills OH, Tuley MR, Baker MD, Plott RT. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol.\u20081998; 139(suppl 2):17\u201322","DOI":"10.1046\/j.1365-2133.1998.1390s2017.x"},{"key":"2021120822585007400_R37","doi-asserted-by":"crossref","unstructured":"Weiss JS, Shavin JS. Adapalene for the treatment of acne vulgaris. J Am Acad Dermatol.\u20081998;39:S50\u2013S54","DOI":"10.1016\/S0190-9622(98)70445-1"},{"key":"2021120822585007400_R38","doi-asserted-by":"crossref","unstructured":"Caron D, Sorba V, Kerrouche N, Clucas A. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. J Am Acad Dermatol.\u20081997;36:S110\u2013S112","DOI":"10.1016\/S0190-9622(97)70052-5"},{"key":"2021120822585007400_R39","doi-asserted-by":"crossref","unstructured":"Millikan LE. Adapalene: an update on newer comparative studies between the various retinoids. Int J Dermatol.\u20082000;39:784\u2013788","DOI":"10.1046\/j.1365-4362.2000.00050.x"},{"key":"2021120822585007400_R40","doi-asserted-by":"crossref","unstructured":"Clucas A, Verschoore M, Sorba V, Poncet M, Baker M, Czernielewski J. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients J Am Acad Dermatol.\u20081997;36:S116\u2013S118","DOI":"10.1016\/S0190-9622(97)70054-9"},{"key":"2021120822585007400_R41","doi-asserted-by":"crossref","unstructured":"Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol.\u20081997;36(suppl 2):S126\u2013S134","DOI":"10.1016\/S0190-9622(97)70056-2"},{"key":"2021120822585007400_R42","doi-asserted-by":"crossref","unstructured":"Pie\u0301rard-Franchimont C, Henry F, Fraiture AL, Fumal I, Pie\u0301rard GE. Split-face clinical and bio-instrumental comparison of 0.1% adapalene and 0.05% tretinoin in facial acne. Dermatology.\u20081999;198:218\u2013222","DOI":"10.1159\/000018117"},{"key":"2021120822585007400_R43","doi-asserted-by":"crossref","unstructured":"Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol.\u20081998;139(suppl 52):34\u201340","DOI":"10.1046\/j.1365-2133.1998.1390s2034.x"},{"key":"2021120822585007400_R44","doi-asserted-by":"crossref","unstructured":"Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol.\u20081998;139(suppl 52):26\u201333","DOI":"10.1046\/j.1365-2133.1998.1390s2026.x"},{"key":"2021120822585007400_R45","doi-asserted-by":"crossref","unstructured":"Wolf JE. An update of recent clinical trials examining adapalene and acne. J Eur Acad Dermatol Venereol.\u20082001;15(suppl 3):23\u201329","DOI":"10.1046\/j.0926-9959.2001.00009.x"},{"key":"2021120822585007400_R46","doi-asserted-by":"crossref","unstructured":"Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol .139(suppl 52): 48\u201356,1998","DOI":"10.1046\/j.1365-2133.1998.1390s2048.x"},{"key":"2021120822585007400_R47","doi-asserted-by":"crossref","unstructured":"Thielitz A, Helmdach M, Rapke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Brit J Dermatol. 2001;145:19\u201327","DOI":"10.1046\/j.1365-2133.2001.04276.x"},{"key":"2021120822585007400_R48","unstructured":"Russell JJ. Topical therapy for acne. Am Fam Physician.\u20082000;61:357\u2013365"},{"key":"2021120822585007400_R49","unstructured":"Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis.\u20081999;63:349\u2013354"},{"key":"2021120822585007400_R50","unstructured":"Bershad S. Topical retinoids in the treatment of acne vulgaris. Cutis.\u20081999;64(suppl 2):8\u201323"},{"key":"2021120822585007400_R51","doi-asserted-by":"crossref","unstructured":"Kakita L. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol.\u20082000;43:S51\u2013S54","DOI":"10.1067\/mjd.2000.108322"},{"key":"2021120822585007400_R52","doi-asserted-by":"crossref","unstructured":"Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A.\u20082005;136:117\u2013121","DOI":"10.1002\/ajmg.a.30744"},{"key":"2021120822585007400_R53","doi-asserted-by":"crossref","unstructured":"Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet.\u20081993;341:1181\u20131182","DOI":"10.1016\/0140-6736(93)91004-6"},{"key":"2021120822585007400_R54","doi-asserted-by":"crossref","unstructured":"Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev.\u20082000;22:218\u2013220","DOI":"10.1016\/S0387-7604(00)00104-2"},{"key":"2021120822585007400_R55","doi-asserted-by":"crossref","unstructured":"Zouboulis CC, Derumeaux L, Decroix J, Mariejewska-Udziela B, Cambazard F, Stuhlert A. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate\/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol.\u20082000;143:498\u2013505","DOI":"10.1111\/j.1365-2133.2000.03701.x"},{"key":"2021120822585007400_R56","doi-asserted-by":"crossref","unstructured":"Wolf JE, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol.\u20082003;49(3 suppl):S211\u2013S217","DOI":"10.1067\/S0190-9622(03)01152-6"},{"key":"2021120822585007400_R57","doi-asserted-by":"crossref","unstructured":"Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed.\u20082005;4:138\u2013146","DOI":"10.1111\/j.1540-9740.2005.04279.x"},{"key":"2021120822585007400_R58","doi-asserted-by":"crossref","unstructured":"Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet.\u20082004;364:2188\u20132195","DOI":"10.1016\/S0140-6736(04)17591-0"},{"key":"2021120822585007400_R59","unstructured":"Meynadier J, Guillot B. Tre\u0301tinoi\u0308ne-e\u0301rythromycine base: leur activite\u0301 anti-inflammatoire. Gaz Med France.\u20081983;90:2551\u20132554"},{"key":"2021120822585007400_R60","doi-asserted-by":"crossref","unstructured":"Parry MF, Rha C-K. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol.\u20081986;122:583\u2013584","DOI":"10.1001\/archderm.122.5.583"},{"key":"2021120822585007400_R61","unstructured":"Kligman AM, Mills OH, McGinley KJ, Leyden JJ. Acne therapy with tretinoin in combination with antibiotics. Acta Derm Venereol Suppl (Stockh).\u20081975;74:111\u2013115"},{"key":"2021120822585007400_R62","unstructured":"White GM. Acne therapy. Adv Dermatol.\u20081999;14:29\u201358; discussion 59"},{"key":"2021120822585007400_R63","doi-asserted-by":"crossref","unstructured":"Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol.\u20081995;132:204\u2013208","DOI":"10.1111\/j.1365-2133.1995.tb05014.x"},{"key":"2021120822585007400_R64","doi-asserted-by":"crossref","unstructured":"Eady EA, Bojar RA, Jones CE, Cove JH, Holland KT, Cunliffe WJ. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol.\u20081996;134:107\u2013113","DOI":"10.1111\/j.1365-2133.1996.tb07847.x"},{"key":"2021120822585007400_R65","doi-asserted-by":"crossref","unstructured":"Leyden JJ, Shalita AR. Rational therapy for acne vulgaris: an update on topical treatment. J Am Acad Dermatol.\u20081986;15:907\u2013915","DOI":"10.1016\/S0190-9622(86)70250-8"},{"key":"2021120822585007400_R66","unstructured":"Kligman AM. Acne vulgaris: tricks and treatments. Part II: The benzoyl peroxide saga. Cutis.\u20081995;56:260\u2013261"},{"key":"2021120822585007400_R67","unstructured":"Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol.\u20082001;11:538\u2013544"},{"key":"2021120822585007400_R68","doi-asserted-by":"crossref","unstructured":"Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol.\u20081998;139:4\u20138","DOI":"10.1046\/j.1365-2133.1998.1390s3004.x"},{"key":"2021120822585007400_R69","doi-asserted-by":"crossref","unstructured":"Eady EA, Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM. Antibiotic resistant propionibacterium in acne: need for policies to modify antibiotic usage. BMJ.\u20081993;306:555\u2013556","DOI":"10.1136\/bmj.306.6877.555"},{"key":"2021120822585007400_R70","doi-asserted-by":"crossref","unstructured":"Eady EA. Bacterial resistance in acne. Dermatology.\u20081998;196:59\u201366","DOI":"10.1159\/000017869"},{"key":"2021120822585007400_R71","doi-asserted-by":"crossref","unstructured":"Meynadier J, Alirezai M. Systemic antibiotics for acne. Dermatology.\u20081998;196:135\u2013139","DOI":"10.1159\/000017847"},{"key":"2021120822585007400_R72","doi-asserted-by":"crossref","unstructured":"Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol.\u20081978;70:51\u201355","DOI":"10.1111\/1523-1747.ep12543487"},{"key":"2021120822585007400_R73","doi-asserted-by":"crossref","unstructured":"Esterly NB, Koransky JS, Furey NL, Trevisan M. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol.\u20081984;120:1308\u20131313","DOI":"10.1001\/archderm.120.10.1308"},{"key":"2021120822585007400_R74","doi-asserted-by":"crossref","unstructured":"Webster GF, McGinley KJ, Leyden JJ. Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol.\u20081981;104:453\u2013457","DOI":"10.1111\/j.1365-2133.1981.tb15317.x"},{"key":"2021120822585007400_R75","doi-asserted-by":"crossref","unstructured":"Krowchuk DP. Treating acne: a practical guide. Med Clin North Am.\u20082000;84:811\u2013828","DOI":"10.1016\/S0025-7125(05)70262-5"},{"key":"2021120822585007400_R76","doi-asserted-by":"crossref","unstructured":"Plewig G, Kligman AM. Acne and Rosacea. 3rd ed. New York, NY: Springer-Verlag; 2000","DOI":"10.1007\/978-3-642-59715-2"},{"key":"2021120822585007400_R77","doi-asserted-by":"crossref","unstructured":"Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol.\u20081996;134:693\u2013695","DOI":"10.1111\/j.1365-2133.1996.tb06972.x"},{"key":"2021120822585007400_R78","doi-asserted-by":"crossref","unstructured":"Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ.\u20081996;312:169\u2013172","DOI":"10.1136\/bmj.312.7024.169"},{"key":"2021120822585007400_R79","unstructured":"Grosshans E, Belaich S, Meynadier J, Alirezai M, Thomas L. A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur J Dermatol.\u20081998;8:161\u2013166"},{"key":"2021120822585007400_R80","doi-asserted-by":"crossref","unstructured":"Landow K. Dispelling myths about acne. Postgrad Med.\u20081997;102:94\u2013112","DOI":"10.3810\/pgm.1997.08.287"},{"key":"2021120822585007400_R81","doi-asserted-by":"crossref","unstructured":"Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol.\u20082006; 54: 242\u2013250","DOI":"10.1016\/j.jaad.2004.10.879"},{"key":"2021120822585007400_R82","doi-asserted-by":"crossref","unstructured":"Katsambas AD. Why and when the treatment of acne fails. Dermatology.\u20081998;196:158\u2013161","DOI":"10.1159\/000017851"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/3\/1188\/1073643\/zpe00906001188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/3\/1188\/1073643\/zpe00906001188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T08:27:00Z","timestamp":1707208020000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/118\/3\/1188\/69419\/Expert-Committee-Recommendations-for-Acne"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":82,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,9,1]]},"published-print":{"date-parts":[[2006,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-2022","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,1]]}}}